tyrosine kinase inhibitors

Rob DillardNon-Small Cell Lung Cancer | October 27, 2023

Three patient case reports showed that osimertinib is a promising and viable treatment option for lung cancer with bone mets.

Patrick DalyNon-Small Cell Lung Cancer | October 16, 2023

Authors of a study, published in Lung Cancer, evaluated real-world data from US patients with metastatic non-squamous ...

Patrick DalyNon-Small Cell Lung Cancer | September 21, 2023

In the recent GAP BRAIN trial, researchers evaluated gefitinib, a tyrosine kinase inhibitor (TKI), with or without ...

Patrick DalyNon-Small Cell Lung Cancer | September 21, 2023

In a recent study, researchers evaluated the safety and efficacy of first-line rezivertinib (BPI-7711), a ...

DocWire News EditorsNon-Small Cell Lung Cancer | September 21, 2023

DocWire News interviews Dr. Joshua Sabari, of the Perlmutter Cancer Center at NYU Langone Health, about recent results ...

Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023

First-line Tagrisso® (osimertinib) improved overall survival (OS) compared with a comparator tyrosine kinase inhibitor ...